RVU120, a small molecule inhibitor of CDK8/19 kinases, enhances rituximab-driven NK cells-mediated cytotoxicity both in vitro and in vivo
نویسندگان
چکیده
Background: NK cells act as one of the most important immunosurveillance mechanisms eliminating cancer cells. recognize Fc portions antibodies binding to surface antigens and release cytotoxic granules cytokines. Antibody-dependent cell-mediated cytotoxicity (ADCC) is major NK-dependent killing mechanisms, activated for example by therapeutic monoclonal antibodies, such anti-CD20 antibody rituximab. cell activity attenuated STAT1 (S727) phosphorylation, mediated CDK8 kinase. Here we show results combination therapy rituximab with a clinical stage CDK8/19 small molecule inhibitor RVU120. Material methods: The effect RVU120 or well their on human was tested in vitro co-culture assay using effector isolated from healthy donors panel CD20-positive diffuse large B-cell lymphoma (DLBCL) lines target impact expression LAMP1 (CD107a) degranulation marker assessed flow cytometry. Pharmacokinetic/pharmacodynamic (PKPD) experiments were performed immunocompetent naïve BALBc C57BL6 mice. Finally vivo effects individually combination, continuous intermittent treatment schemes Rag2−/− mice inoculated Raji CD20+ line. Ex analyses murine splenocytes YAC-1 line population. phenotype monitored blood throughout study, spleens at end experiment. Results: In demonstrated that causes upregulation level increases against DLBCL lines. Short-term increased maturation cells, confirmed ex assay. Chronic, administration less effective showed signs exhaustion, both vivo. tumour bearing mice, not effective, whereas caused significant inhibition growth. Combined tolerated animals resulted complete regressions. treated highest potential Conclusions: significantly rituximab-driven ADCC, resulting regression. This strategy may be useful enhancing anti-cancer other antibody-drug conjugates, potentially leading deep responses. Conflict interest: Ownership: Ryvu Therapeutics
منابع مشابه
Small Molecule-BIO Accelerates and Enhances Marrow-Derived Mesenchymal Stem Cell in Vitro Chondrogenesis
Background: Hyaline cartilage defects exhibit a major challenge in the field of orthopedic surgery owing to its limited repair capacity. On the other hand, mesenchymal stem cells (MSCs) are regarded as potent cells with a property of cartilage regeneration. We aimed to optimize marrow-derived MSC chondrogenic culture using a small bioactive molecule referred to as BIO. Methods: MSCs from the ma...
متن کاملLepista sordida Water Extract Enhances the Maturation of Mouse Dendritic Cells in Vitro and in Vivo
متن کامل
Small Molecule Therapeutics A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
Using a high-throughput screening (HTS) approach, we have identified and validated several smallmolecule Mcl-1 inhibitors (SMI). Here, we describe a novel selective Mcl-1 SMI inhibitor, 2 (UMI-77), developed by structure-based chemical modifications of the lead compound 1 (UMI-59). We have characterized the binding of UMI-77 to Mcl-1 by using complementary biochemical, biophysical, and computat...
متن کاملMechanisms by Which Low Glucose Enhances the Cytotoxicity of Metformin to Cancer Cells Both In Vitro and In Vivo
Different cancer cells exhibit altered sensitivity to metformin treatment. Recent studies suggest these findings may be due in part to the common cell culture practice of utilizing high glucose, and when glucose is lowered, metformin becomes increasingly cytotoxic to cancer cells. In low glucose conditions ranging from 0 to 5 mM, metformin was cytotoxic to breast cancer cell lines MCF7, MDAMB23...
متن کاملSC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo.
PURPOSE Glioblastomas are among the most lethal neoplasms, with a median survival of <1 year. Modulation of the proteasome function has emerged as a novel approach to cancer pharmacotherapy. Here, we characterized the antitumor properties of SC68896, a novel small molecule proteasome inhibitor. EXPERIMENTAL DESIGN Different tumor cell lines were tested by crystal violet staining for sensitivi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer
سال: 2022
ISSN: ['0959-8049', '1879-0852']
DOI: https://doi.org/10.1016/s0959-8049(22)00952-2